Heritable genetic intervention
is no longer theoretical.

Dozens of children worldwide have now been born using 
mitochondrial replacement therapy (MRT).

A technique designed to prevent the transmission of severe mitochondrial disease. These births represent the first clinically implemented form of regulated germline intervention.

The foundational scientific work was pioneered in the United States by Shoukhrat Mitalipov, PhD, demonstrating that pathogenic mitochondrial DNA can be replaced while preserving the parents’ nuclear genome.

While U.S. federal policy has constrained domestic clinical deployment, other advanced regulatory jurisdictions have moved forward. The United Kingdom established the first national licensing framework for MRT, followed by enabling legislation in Australia.


MRT addresses mitochondrial DNA disorders. Precision germline genome editing extends this framework to nuclear DNA mutations responsible for thousands of severe monogenic diseases.

Advances in gene correction technology may address serious inherited conditions such as heritable cancer syndromes, cystic fibrosis, Huntington’s disease, sickle cell disease, and spinal muscular atrophy, by targeting disease-causing mutations at their source and working toward reducing transmission risk to future generations.

Together, these technologies form the foundation of the next
 generation of reproductive genetic medicine.

Origin Genomics is building at the intersection of these advances: developing precision correction platforms designed for regulatory readiness, safety validation, and scalable clinical translation.